These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1539460)

  • 1. Evaluation of measles vaccination programme conducted in two separate health centres.
    Onoja AL; Adu FD; Tomori O
    Vaccine; 1992; 10(1):49-52. PubMed ID: 1539460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles control in a rural area in Zimbabwe.
    Tumwine JK
    East Afr Med J; 1991 Sep; 68(9):694-701. PubMed ID: 1797531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
    Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
    J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced seroconversion to measles in infants given vitamin A with measles vaccination.
    Semba RD; Munasir Z; Beeler J; Akib A; Muhilal ; Audet S; Sommer A
    Lancet; 1995 May; 345(8961):1330-2. PubMed ID: 7752754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from measles vaccination in developing countries.
    Hall AJ; Cutts FT
    BMJ; 1993 Nov; 307(6915):1294-5. PubMed ID: 8257878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded programme on immunization (EPI). Safety of high titre measles vaccines.
    Wkly Epidemiol Rec; 1992 Nov; 67(48):357-61. PubMed ID: 1449986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
    Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a mass measles immunization campaign in Yaoundé, Cameroun.
    McBean AM; Foster SO; Herrmann KL; Gateff C
    Trans R Soc Trop Med Hyg; 1976; 70(3):206-12. PubMed ID: 982514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low seroconversion rates to measles vaccine among children in Nigeria.
    Adu FD; Akinwolere OA; Tomori O; Uche LN
    Bull World Health Organ; 1992; 70(4):457-60. PubMed ID: 1394778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
    Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
    BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age for measles immunization seroconversion after measles vaccination at 6-8 months of age--a randomized controlled trial.
    Deivanayagam N; Ramamurthy N; Krishnamurthy PV; Shankar VJ; Ashok TP; Nedunchelian K; Mala N; Ahmed SS
    Indian Pediatr; 1990 Nov; 27(11):1171-6. PubMed ID: 2081639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa.
    Benn CS; Aaby P; Balé C; Olsen J; Michaelsen KF; George E; Whittle H
    Lancet; 1997 Jul; 350(9071):101-5. PubMed ID: 9228962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to measles immunization in rural Ghanaian infants.
    Sakatoku H; Nakano T; Arai S; Afari EA
    J Trop Pediatr; 1994 Oct; 40(5):291-3. PubMed ID: 7807624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Child mortality following standard, medium or high titre measles immunization in West Africa.
    Knudsen KM; Aaby P; Whittle H; Rowe M; Samb B; Simondon F; Sterne J; Fine P
    Int J Epidemiol; 1996 Jun; 25(3):665-73. PubMed ID: 8671571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion rates and measles antibody titers induced by measles vaccination in Latin American children six to 12 months of age.
    Rev Infect Dis; 1983; 5(3):596-605. PubMed ID: 6879022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.
    Whittle HC; Rowland MG; Mann GF; Lamb WH; Lewis RA
    Lancet; 1984 Oct; 2(8407):834-7. PubMed ID: 6148572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston Zagreb vaccine at age 6 months.
    Cutts FT; Othepa O; Vernon AA; Nyandu B; Markowitz LE; Deforest A; Wilkins K; Okwo B
    Int J Epidemiol; 1994 Jun; 23(3):624-31. PubMed ID: 7960392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of immune response in infants with different nutritional status: vaccinated against tuberculosis, measles and poliomyelitis.
    Adeiga AA; Akinosho RO; Onyewuche J
    J Trop Pediatr; 1994 Dec; 40(6):345-50. PubMed ID: 7853439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy.
    Garly ML; Martins CL; Balé C; da Costa F; Dias F; Whittle H; Aaby P
    Int J Epidemiol; 1999 Apr; 28(2):347-52. PubMed ID: 10342702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles HI-antibody levels in Lagos children, Nigeria: a follow-up study to resurgence of measles in Lagos metropolis.
    Oyefolu AO; Omilabu SA
    West Afr J Med; 2001; 20(3):238-42. PubMed ID: 11922159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.